Aim: Urokinase plasminogen activator (uPA) has been scarcely studied in veterinary oncology. The aim of this study was to determine the uPA serum concentrations in healthy and oncologic canine patients and to investigate its potential value as a tumor biomarker.

Materials and Methods: Serum uPA concentrations of healthy and oncologic canine patients were measured by enzyme-linked immunosorbent assay. Their relationships with the dogs' health status and tumor characteristics were analyzed through ANOVA and independent t-test.

Results: There were no significant differences between mean serum values (±standard deviation) of healthy dogs (0.19±0.13 ng/ml) and oncologic canine patients (0.22±0.33 ng/ml), or between dogs with benign or malignant tumors, and with or without metastases, although the latter tended to show higher uPA serum levels.

Conclusion: This is the first study describing the uPA serum levels in dogs. Although its results do not support uPA as a tumor biomarker, higher uPA levels in dogs with metastatic neoplasms may reflect the role of the enzyme in tumor progression.

Keywords: biomarker, dogs, neoplasms, serum, urokinase plasminogen activator.

1. Schrohl, A.S., Holten-Andersen, M., Sweep, F., Schmitt, M., Harbeck, N., Foekens, J. and Brunner, N. (2003) Tumor markers: From laboratory to clinical utility. Mol. Cell. Proteomics, 2(6): 378-387. [Crossref] [PubMed]

2. Lilja, H., Babaian, R., Dowell, B., Klee, G.G., Rittenhouse, H., Semjonow, A., Shih, I.E.M., Sibley, P. and Soletormos, G. (2009) Tumor markers in prostate cancer. In: Sturgeon, C.M., Diamandis, E.P., editors. Laboratory Medicine Practice Guidelines - Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. 1st ed. NACB, Washington, DC. p16.

3. Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M.R., Hayes, D.F. and Bast, R.C. (2007) American society of clinical oncology 2007-update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol., 25(33): 5287-5312. [Crossref] [PubMed]

4. Ulisse, S., Baldini, E., Sorrenti, S. and D'Armiento, M. (2009) The urokinase plasminogen activator system: A target for anti-cancer therapy. Curr. Cancer Drug Targets, 9(1): 32-71. [Crossref]

5. Lijnen, H.R. (2005) Pleiotropic functions of plasminogen activator inhibitor-1. J. Thromb. Haemost., 3(1): 35-45. [Crossref] [PubMed]

6. Mekkawy, A.H., Pourgholami, M.H. and Morris, D.L. (2014) Involvement of urokinase-type plasminogen activator system in cancer: An overview. Med. Res. Rev., 34(5): 918-956. [Crossref] [PubMed]

7. Andreasen, P.A., Kjoller, L., Christensen, L. and Duffy, M.J. (1997) The urokinase-type plasminogen activator system in cancer metastasis: A review. Int. J. Cancer, 72(1): 1-22. [Crossref]

8. Duffy, M.J. and Duggan, C. (2004) The urokinase plasminogen activator system: A rich source of tumour markers for the individualized management of patients with cancer. Clin. Biochem., 37(7): 541-548. [Crossref] [PubMed]

9. Ferraris, G.M.S. and Sidenius, N. (2013) Urokinase plasminogen activator receptor: A functional integrator of extracellular proteolysis, cell adhesion, and signal transduction. Semin. Thromb. Hemost., 39(4): 347-355. [Crossref] [PubMed]

10. de Munk, G.A.W. and Rijken, D.C. (1990) Fibrinolytic properties of single chain urokinase-type plasminogen activator (pro-urokinase). Fibrinolysis, 4(1): 1-9. [Crossref]

11. Ellis, V. (2003) Plasminogen activators: Structure and function. In: Waisman, D.M., editor. Plasminogen: Structure, Activation, and Regulation. 1st ed. Springer, New York. p19-21. [Crossref]

12. Cines, D.B., Pollak, E.S., Buck, C.A., Loscalzo, J., Zimmerman, G.A., McEver, R.P., Pober, J.S., Wick, T.M., Konkle, B.A. and Schwartz, B.S. (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. J. Am. Soc. Hematol., 91(10): 3527-3561.

13. Cozzi, P.J., Wang, J., Delprado, W., Madigan, M.C., Fairy, S., Russell, P.J. and Li, Y. (2006) Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum. Pathol., 37(11): 1442-1451. [Crossref] [PubMed]

14. Stepanova, V.V. and Tkachuk, V.A. (2002) Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry, 67(1): 109-118. [PubMed]

15. Foekens, J.A., Peters, H.A., Look, M.P., Portengen, H., Schmitt, M., Kramer, M.D., Brunner, N., Janicke, F., Meijer-van Gelder, M.E. and Henzen-Logmans, S.C. (2000) The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res., 60(3): 636-643. [PubMed]

16. Harbeck, N., Kates, R.E. and Schmitt, M. (2002) Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor Type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J. Clin. Oncol., 20(4): 1000-1007. [Crossref] [PubMed]

17. Look, M.P., van Putten, W.L.J., Duffy, M.J., Harbeck, N., Christensen, I.J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., Sweep, C.G. and Ulm, K. (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst., 94(2): 116-128. [Crossref]

18. Harbeck, N., Schmitt, M., Meisner, C., Friedel, C., Untch, M., Schmidt, M., Sweep, C.G.J., Lisboa, B.W., Lux, M.P., Beck, T., Hasmuller, S., Kiechle, M. and Janicke, F. (2013) Ten-year analysis of the prospective multicenter Chemo-N0 trial validates American society of clinical oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur. J. Cancer, 49(8): 1825-1835. [Crossref] [PubMed]

19. Margheri, F., D'Alessio, S., Serrati, S., Pucci, M., Annunziato, F., Cosmi, L., Liotta, F., Angeli, R., Angelucci, A., Gravina, G.L. and Rucci, N. (2005) Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Genet. Ther., 12(8): 702-714. [Crossref] [PubMed]

20. Sawai, H., Liu, J., Reber, H.A., Hines, O.J. and Eibl, G. (2006) Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol. Cancer Res., 4(3): 159-167. [Crossref] [PubMed]

21. Kobayashi, H., Sugino, D., She, M.Y., Ohi, H., Hirashima, Y., Shinohara, H., Fujie, M., Shibata, K. and Terao, T. (1998) A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur. J. Biochem., 253(3): 817-826. [Crossref]

22. Szende, B., Okada, Y., Tsuda, Y., Horvath, A., Bokonyi, G., Okamoto, S., Wanaka, K. and Keri, G. (2002) A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number. In Vivo, 16(5): 281-286. [PubMed]

23. Ploug, M., Ostergaard, S., Gardsvoll, H., Kovalski, K., Holst-Hansen, C., Holm, A., Ossowski, L. and Dano, K. (2001) Peptide-derived antagonists of the urokinase receptor-affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intrastation. Biochemistry, 40(40): 12157-12168. [Crossref]

24. Hu, X.W., Duan, H.F., Pan, S.Y., Li, Y.M., Xi, Y., Zhao, S.R., Yin, L., Li, J.F., Chen, H.P. and Wu, C.T. (2016) Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. Cance Biol. Ther., 7(5): 651-659. [Crossref]

25. Pluijm, G., Sijmons, B., Vloedgraven, H., van der Bent, C., Drijfhout, J.W., Verheijen, J., Quax, P., Karperien, M., Papapoulos, S. and Lowik, C. (2001) Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am. J. Pathol., 159(3): 971-982. [Crossref]

26. Vallera, D.A., Li, C., Jin, N., Panoskaltsis-Mortari, A. and Hall, W.A. (2002) Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J. Natl. Cancer Inst., 94(8): 597-606. [Crossref]

27. Rono, B., Romer, J., Liu, S., Bugge, T.H., Leppla, S.H. and Kristjansen, P.E.G. (2006) Antitumor efficacy of a urokinase activation-dependent anthrax toxin. Mol. Cancer Ther., 5(1): 89-96. [Crossref] [PubMed]

28. Su, S.C., Lin, C.W., Yang, W.E., Fan, W.L. and Yang, S.F. (2015) The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin. Ther. Targets, 20(5): 551-566. [Crossref] [PubMed]

29. Strojan, P., Budihna, M., Smid, L., Vrhovec, I. and Skrk, J. (1998) Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor Type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur. J. Cancer, 34(8): 1193-1197. [Crossref]

30. Konukoglu, D., Turhan, M.S., Celik, V. and Turna, H. (2007) Relation of serum vascular endothelial growth factor as an angiogenesis biomarker with nitric oxide and urokinase-type plasminogen activator in breast cancer patients. Indian J. Med. Res., 125(6): 747-751. [PubMed]

31. Zhang, W., Ling, D., Tan, J., Zhang, J. and Li, L. (2013) Expression of urokinase plasminogen activator and plasminogen activator inhibitor Type-1 in ovarian cancer and its clinical significance. Oncol. Rep., 29(2): 637-645. [PubMed]

32. Miyake, H., Hara, I., Yamanaka, K., Gohji, K., Arakawa, S. and Kamidono, S. (1999) Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate, 39(2): 123-129. [Crossref]

33. Santos, A., Lopes, C., Marques, R.M., Amorim, I., Ribeiro, J., Frias, C., Vicente, C., Gartner, F. and de Matos, A. (2010) Immunohistochemically analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours. Vet. J., 189(1): 43-48. [Crossref] [PubMed]

34. Santos, A.A., Lopes, C.C., Ribeiro, J.R., Martins, L.R., Santos, J.C., Amorim, I.F., Gartner, F. and Matos, A.J. (2013) Identification of prognostic factors in canine mammary malignant tumours: A multivariable survival study. BMC Vet. Res., 9(1): 1-11. [Crossref]

35. Golshahi, H., Tavasoly, A., Rezaie, A. and Farhadi, M. (2013) Urokinase plasminogen activator expression in canine malignant mammary tumours by immunohistochemically study. Bull. Vet. Inst. Pulawy, 57(4): 587-591. [Crossref]

36. Schappa, J.T., Frantz, A.M., Gorden, B.H., Dickerson, E.B., Vallera, D.A. and Modiano, J.F. (2013) Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors. Int. J. Cancer, 133(8): 1936-1944. [Crossref] [PubMed] [PMC]

37. Anwar, S., Yanai, T. and Sakai, H. (2015) Immunohistochemical detection of urokinase plasminogen activator and urokinase plasminogen activator receptor in canine vascular endothelial tumours. J. Comp. Pathol., 153: 278-282. [Crossref] [PubMed]

38. Faleiro, M.R., Toledo, D.C., Rodrigues, M.M.P., Amorim, R.L., Brito, L.A.B., Damasceno, A.D. and Moura, V.M.B.D. (2013) uPAR expression in canine normal prostate and with proliferative disorders. Cienc. Anim. Bras., 14(2): 237-244.

39. Leonardi, L., Quattrini, I., Roperto, F. and Benassi, M.S. (2013) Protease expression in giant cell tumour of bone: A comparative study on feline and human samples. Res. Vet. Sci., 95(2): 310-315. [Crossref] [PubMed]

40. Diez, M. and Nguyen, P. (2006) Obesity: Epidemiology, pathophysiology and management of the obese dog. In: Pibot, P., Biourge, V., Elliot, D., editors. Encyclopedia of Canine Clinical Nutrition. 1st ed. Aniwa SAS, France. p22.

41. Cobos, E., Jumper, C. and Lox, C. (2003) Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer. Clin. Appl. Thromb. Hemost., 9(3): 241-246. [Crossref]

42. Gibbs, J.F., Schlieman, M., Singh, P., Saxena, R., Martinick, M., Hutson, A.D. and Corasanti, J. (2009) A pilot study of urokinase-type plasminogen activator (uPA) overexpression in the brush cytology of patients with malignant pancreatic or biliary strictures. HPB Surg., 2009: Article ID: 805971, 5. [Crossref]

43. Winter, K., Szczesniak, P., Bulska, M., Kumor-Kisielewska, A., Durko, L., Gasiorowska, A., Orszulak-Michalak, D. and Malecka-Panas, E. (2015) Serum level of urokinase plasminogen activator (uPA) correlates with the survival of patients with pancreatic ductal adenocarcinoma (PDAC). Pancreact. Disord. Ther., 5(3): 1-6.

44. Gustafsson, A., Ajeti, V. and Ljunggren, L. (2011) Detection of supAR in the saliva of healthy young adults: Comparison with plasma levels. Biomark Insights, 6: 119-125. [Crossref] [PubMed] [PMC]

45. Yu, L., Long, D., Wu, X.L., Yang, J.H., Yang, Y.C., Feng, G. and Li, Y. (2011) Prognostic significance of urokinase-type plasminogen activator and its receptor in patients with systemic inflammatory response syndrome. World J. Emerg. Surg., 2(3): 185-189. [Crossref] [PubMed] [PMC]

46. Maguire, T., Chin, D., Soutar, D. and Duffy, M.J. (2000) Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin. Int. J. Cancer, 85(4): 457-459. [Crossref]

47. Dublin, E., Hanby, A., Patel, N.K., Liebman, R. and Barnes, D. (2000) Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Am. J. Pathol., 157(4): 1219-1227. [Crossref]

48. Narod, S.A. (2012) Tumour size predicts long-term survival among women with lymph node-positive breast cancer. Curr. Oncol., 19(5): 249-253. [Crossref]